Nuevo documento de word 2007 (4)
•Download as DOCX, PDF•
0 likes•158 views
This study protocol describes a randomized controlled trial to assess whether magnesium sulfate compared to placebo administered to women at risk of preterm birth between 30-34 weeks reduces the risk of death or cerebral palsy in children at two years of age. The trial will randomize over 1676 women to receive either magnesium sulfate or placebo by IV infusion within 24 hours of planned or expected preterm birth. The primary outcome will be death or cerebral palsy in children at two years of age. The trial aims to provide evidence on whether the neuroprotective benefits of magnesium sulfate seen at earlier gestations apply at 30-34 weeks.
Report
Share
Report
Share
![BMC Pregnancy Childbirth. 2013 Apr 9;13:91. doi: 10.1186/1471-2393-13-91.
Magnesium sulphate at 30 to 34 weeks' gestationalage:
neuroprotectiontrial (MAGENTA)--studyprotocol.
Crowther CA1
, Middleton PF, Wilkinson D, Ashwood P, Haslam R; MAGENTA Study Group.
Author information
1
Australian Research Centre for Health of Women and Babies (ARCH), The Robinson
Institute, The University of Adelaide, Adelaide, Australia.
caroline.crowther@adelaide.edu.au
Abstract
BACKGROUND:
Magnesium sulphate is currently recommended for neuroprotection of preterm infants for women at
risk of preterm birth at less than 30 weeks' gestation, based on high quality evidence of benefit.
However there remains uncertainty as to whether these benefits apply at higher gestational
ages.The aim of this randomised controlled trial is to assess whether giving magnesium sulphate
compared with placebo to women immediately prior to preterm birth between 30 and 34 weeks'
gestation reduces the risk of death or cerebral palsy in their children at two years' corrected age.
METHODS/DESIGN:
DESIGN:
Randomised, multicentre, placebo controlled trial.
INCLUSION CRITERIA:
Women, giving informed consent, at risk of preterm birth between 30 to 34 weeks' gestation, where
birth is planned or definitely expected within 24 hours, with a singleton or twin pregnancy and no
contraindications to the use of magnesium sulphate.Trial entry & randomisation: Eligible women will
be randomly allocated to receive either magnesium sulphate or placebo.Treatment groups: Women
in the magnesium sulphate group will be administered 50 ml of a 100 ml infusion bag containing 8 g
magnesium sulphate heptahydrate [16 mmol magnesium ions]. Women in the placebo group will be
administered 50 ml of a 100 ml infusion bag containing isotonic sodium chloride solution (0.9%).
Both treatments will be administered through a dedicated IV infusion line over 30 minutes.Primary
study outcome: Death or cerebral palsy measured in children at two years' corrected age.
SAMPLE SIZE:
1676 children are required to detect a decrease in the combined outcome of death or cerebral
palsy, from 9.6% with placebo to 5.4% with magnesium sulphate (two-sided alpha 0.05, 80%
power, 5% loss to follow up, design effect 1.2).
DISCUSSION:](https://image.slidesharecdn.com/nuevodocumentodeword20074-150530220534-lva1-app6892/85/Nuevo-documento-de-word-2007-4-1-320.jpg)
![Given the magnitude of the protective effect in the systematic review, the ongoing uncertainty about
benefits at later gestational ages, the serious health and cost consequences of cerebral palsy for
the child, family and society, a trial of magnesium sulphate for women at risk of preterm birth
between 30 to 34 weeks' gestation is both important and relevant for clinical practice globally.
TRIAL REGISTRATION:
Australian New Zealand Clinical Trials Registry - ACTRN12611000491965.
PMID:
23570677
[PubMed - indexed for MEDLINE]
PMCID:
PMC3636106
Free PMC Article](data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7)
Recommended
Cd009395 abstract
This Cochrane review examines whether magnesium sulfate administered to women at term protects the fetus from brain injury. The review included one small randomized controlled trial involving 135 women with mild preeclampsia. The trial found no significant differences in outcomes like Apgar scores or gestational age between infants whose mothers received magnesium sulfate or placebo. Maternal side effects like warmth and flushing were more common with magnesium sulfate, but serious side effects causing treatment cessation were not. Larger trials are still needed to determine if magnesium sulfate provides neuroprotective benefits for term infants.
Cd010846 abstract.
This Cochrane review summarizes the current evidence on using creatine supplementation during pregnancy to protect the developing fetus's brain. The review found no randomized controlled trials examining the effects of creatine supplementation for fetal neuroprotection. While animal studies suggest creatine may protect the fetal brain, high-quality randomized trials are still needed to establish the safety and efficacy of creatine supplementation during human pregnancy. Such trials should evaluate both short- and long-term maternal and infant outcomes, including rates of neurodevelopmental disabilities in childhood.
Abstract for SHPE Conference
There are over 25 million people in the United States suffering from diabetes. For those with type 1 diabetes, extreme fluctuations in blood glucose levels can cause health issues. The researchers aimed to create a closed-loop system to automatically administer the correct insulin dose by accurately modeling blood glucose concentration (BGC) based on food intake, activity, and stress levels. The researchers modeled type 1 diabetes cases using carbohydrate intake, bolus insulin, and basal insulin as inputs. They tested modified Wiener block modeling on data collected over 3-5 days from several subjects. While some cases produced good results, the researchers concluded that more than three days of data is generally needed to develop an accurate glucose model.
Actos And Metformin In Women With Polycystic Ovary
This study evaluated the efficacy and safety of adding Actos (pioglitazone) to metformin treatment in women with polycystic ovary syndrome (PCOS) who did not respond optimally to metformin alone. The study found that in women whose PCOS symptoms were not improved by metformin, the addition of Actos led to reductions in insulin levels, insulin resistance, and androgen levels, as well as improved menstrual regularity, without any safety issues.
Nuevo documento de word 2007 (15)
This study evaluated the association between intrapartum magnesium sulfate (MgSO4) exposure for fetal neuroprotection and delivery room resuscitation needs and neonatal outcomes among preterm infants. The study reviewed data on 6,015 preterm infants born between 23-31 weeks gestation in Canadian neonatal intensive care units between 2011-2012. 1,387 infants (23.1%) were exposed to intrapartum MgSO4. The primary outcome of intensive resuscitation needs, defined as requiring intubation/ventilation, chest compressions or epinephrine, was compared between exposed and unexposed infants. After adjusting for confounders, there was no significant difference in intensive resuscitation needs between groups. MgSO4 exposure
Physio ex exercise 4 activity 3
The document summarizes an experiment examining the effects of hormone replacement therapy on osteoporosis in ovariectomized rats. The experiment involved injecting one rat with saline as a control, one rat with estrogen, and one rat with calcitonin, and measuring their vertebral bone density via T-scores after 7 days. Estrogen injections led to increased bone density as predicted, while calcitonin injections unexpectedly decreased bone density. The results highlight the complex roles of hormones like estrogen and calcitonin in preventing osteoporosis.
Nuevo documento de word 2007 (27)
This study examined the association between neonatal magnesium levels and long-term motor outcomes in 75 preterm infants weighing less than 1500g. The study found that higher average serum magnesium levels during the neonatal period were correlated with a decreased risk of abnormal motor exam later in life. While higher magnesium levels also showed a lower risk of epilepsy, this finding did not reach statistical significance. The study demonstrates a link between higher neonatal magnesium and improved long-term motor function and suggests larger studies are needed to further evaluate if magnesium supplementation can enhance neurodevelopmental outcomes for premature infants.
Mental work
This document summarizes research from Laval University in Quebec on preventing obesity. It presents several key findings:
1) Mental work, like reading and writing tasks, increases spontaneous energy intake compared to resting. Completing computerized tests also increases workload, reaction times, and glucose instability versus a control condition.
2) A sport-studies program combining academic classes, physical activity, and hockey instruction led to decreased BMI and improved fitness while maintaining academic success in students.
3) Researchers at Laval University hold weekly running meetings to discuss obesity prevention and treatment research, believing it increases productivity and focus compared to stationary meetings.
Recommended
Cd009395 abstract
This Cochrane review examines whether magnesium sulfate administered to women at term protects the fetus from brain injury. The review included one small randomized controlled trial involving 135 women with mild preeclampsia. The trial found no significant differences in outcomes like Apgar scores or gestational age between infants whose mothers received magnesium sulfate or placebo. Maternal side effects like warmth and flushing were more common with magnesium sulfate, but serious side effects causing treatment cessation were not. Larger trials are still needed to determine if magnesium sulfate provides neuroprotective benefits for term infants.
Cd010846 abstract.
This Cochrane review summarizes the current evidence on using creatine supplementation during pregnancy to protect the developing fetus's brain. The review found no randomized controlled trials examining the effects of creatine supplementation for fetal neuroprotection. While animal studies suggest creatine may protect the fetal brain, high-quality randomized trials are still needed to establish the safety and efficacy of creatine supplementation during human pregnancy. Such trials should evaluate both short- and long-term maternal and infant outcomes, including rates of neurodevelopmental disabilities in childhood.
Abstract for SHPE Conference
There are over 25 million people in the United States suffering from diabetes. For those with type 1 diabetes, extreme fluctuations in blood glucose levels can cause health issues. The researchers aimed to create a closed-loop system to automatically administer the correct insulin dose by accurately modeling blood glucose concentration (BGC) based on food intake, activity, and stress levels. The researchers modeled type 1 diabetes cases using carbohydrate intake, bolus insulin, and basal insulin as inputs. They tested modified Wiener block modeling on data collected over 3-5 days from several subjects. While some cases produced good results, the researchers concluded that more than three days of data is generally needed to develop an accurate glucose model.
Actos And Metformin In Women With Polycystic Ovary
This study evaluated the efficacy and safety of adding Actos (pioglitazone) to metformin treatment in women with polycystic ovary syndrome (PCOS) who did not respond optimally to metformin alone. The study found that in women whose PCOS symptoms were not improved by metformin, the addition of Actos led to reductions in insulin levels, insulin resistance, and androgen levels, as well as improved menstrual regularity, without any safety issues.
Nuevo documento de word 2007 (15)
This study evaluated the association between intrapartum magnesium sulfate (MgSO4) exposure for fetal neuroprotection and delivery room resuscitation needs and neonatal outcomes among preterm infants. The study reviewed data on 6,015 preterm infants born between 23-31 weeks gestation in Canadian neonatal intensive care units between 2011-2012. 1,387 infants (23.1%) were exposed to intrapartum MgSO4. The primary outcome of intensive resuscitation needs, defined as requiring intubation/ventilation, chest compressions or epinephrine, was compared between exposed and unexposed infants. After adjusting for confounders, there was no significant difference in intensive resuscitation needs between groups. MgSO4 exposure
Physio ex exercise 4 activity 3
The document summarizes an experiment examining the effects of hormone replacement therapy on osteoporosis in ovariectomized rats. The experiment involved injecting one rat with saline as a control, one rat with estrogen, and one rat with calcitonin, and measuring their vertebral bone density via T-scores after 7 days. Estrogen injections led to increased bone density as predicted, while calcitonin injections unexpectedly decreased bone density. The results highlight the complex roles of hormones like estrogen and calcitonin in preventing osteoporosis.
Nuevo documento de word 2007 (27)
This study examined the association between neonatal magnesium levels and long-term motor outcomes in 75 preterm infants weighing less than 1500g. The study found that higher average serum magnesium levels during the neonatal period were correlated with a decreased risk of abnormal motor exam later in life. While higher magnesium levels also showed a lower risk of epilepsy, this finding did not reach statistical significance. The study demonstrates a link between higher neonatal magnesium and improved long-term motor function and suggests larger studies are needed to further evaluate if magnesium supplementation can enhance neurodevelopmental outcomes for premature infants.
Mental work
This document summarizes research from Laval University in Quebec on preventing obesity. It presents several key findings:
1) Mental work, like reading and writing tasks, increases spontaneous energy intake compared to resting. Completing computerized tests also increases workload, reaction times, and glucose instability versus a control condition.
2) A sport-studies program combining academic classes, physical activity, and hockey instruction led to decreased BMI and improved fitness while maintaining academic success in students.
3) Researchers at Laval University hold weekly running meetings to discuss obesity prevention and treatment research, believing it increases productivity and focus compared to stationary meetings.
1471 2393-13-91
This study aims to assess whether giving magnesium sulfate compared to placebo to women at risk of preterm birth between 30-34 weeks reduces the risk of death or cerebral palsy in children at two years. The study will randomly assign over 1600 women to receive either magnesium sulfate or placebo. The primary outcome measured will be death or cerebral palsy in children at two years. Previous studies have shown magnesium sulfate may reduce the risk of cerebral palsy in preterm infants, but the benefits at later gestational ages are uncertain, motivating this clinical trial.
Cd004661 abstract
This Cochrane review examines the effects of magnesium sulfate given to women at risk of preterm birth to protect the fetus's brain. The review found that magnesium sulfate significantly reduced the risk of cerebral palsy in preterm infants by 32% and reduced substantial gross motor dysfunction by 39%. No significant effects were found for pediatric mortality or other neurological impairments. Magnesium sulfate was found to have minor side effects for mothers but no significant effects on major maternal complications. The review concludes that magnesium sulfate has a established neuroprotective role for preterm fetuses.
Nej me0805018
This editorial discusses a recent randomized controlled trial that evaluated the use of bortezomib plus melphalan and prednisone compared to melphalan and prednisone alone for the initial treatment of multiple myeloma in patients who were not eligible for stem cell transplantation. The trial found that the combination of bortezomib provided superior outcomes, including higher response rates and longer duration of response. However, the editorial cautions that to effectively apply these results, comparisons need to be made to other available treatment options, long-term outcomes need to be evaluated, and toxic effects on quality of life considered. Overall progress is being made in multiple myeloma treatment, but further research is still needed.
01
1) Magnesium sulfate has been shown to provide neuroprotective effects for extremely premature infants by reducing cerebral injury and cell death.
2) While some studies found magnesium sulfate to be neuroprotective, others did not find sustainable effects, so more randomized studies were conducted.
3) A Cochrane review of 5 randomized trials found magnesium sulfate significantly reduced the risk of cerebral palsy in premature infants without increasing mortality risks for mother or infant.
Cd009395 standard
This review examines the effectiveness of magnesium sulfate given to women at term to protect the fetus from brain injury and neurodevelopmental disabilities like cerebral palsy. The review included one randomized controlled trial with 135 women with mild preeclampsia at term. The trial found no significant differences in infant outcomes like Apgar scores or gestational age between the magnesium sulfate and placebo groups. Maternal side effects were more common with magnesium sulfate, but severe side effects causing treatment cessation were similar between groups. Larger trials are still needed to determine if magnesium sulfate provides neuroprotection for infants when administered at term.
Bain et al-2014-bjog__an_international_journal_of_obstetrics_&_gynaecology
1) The study evaluated different loading infusion rates (60 minutes vs 20 minutes) of magnesium sulfate given to women before 30 weeks gestation for preterm fetal neuroprotection.
2) Overall, 71% of women experienced adverse effects during the first hour of infusion, with no significant difference between the 60-minute (60%) and 20-minute (81%) groups.
3) Women in the 60-minute group experienced significantly less warmth and flushing at 20 minutes into the infusion compared to the 20-minute group, but there were no other significant differences in adverse effects between the groups.
Magnesium sulfate
The document discusses evidence that magnesium sulfate administered to mothers at risk of preterm birth reduces the risk of cerebral palsy in infants. Several large randomized controlled trials and meta-analyses involving over 15,000 women found magnesium sulfate decreased the risk of cerebral palsy without increasing mortality. The number needed to treat to prevent one case of cerebral palsy is estimated at 63 women. The document also describes a modified magnesium sulfate neuroprotection protocol used at Riverside Hospital for imminent preterm deliveries between 23 and 33 weeks.
Magnesium sulfate
The document discusses evidence that magnesium sulfate administered to mothers at risk of preterm birth reduces the risk of cerebral palsy in infants. Several large randomized controlled trials and meta-analyses involving over 15,000 women found magnesium sulfate decreased the risk of cerebral palsy without increasing mortality. The number needed to treat to prevent one case of cerebral palsy is estimated at 63 women. The document also describes a modified magnesium sulfate neuroprotection protocol used at Riverside Hospital for imminent preterm deliveries between 23 and 33 weeks.
Health in infants born to mothers who received mefloquine or sulphadoxine pyr...
Attention ADF Female Veterans who were administered Mefloquine prior,during and after deployments overseas.
Dr Jane Quinn (Spokesperson for Mefloquine and Tafenoquine (Mef n Taf) Veterans Australia group)
BScu(U Westminister),PhD (Edin) quoted:
This study does show that mefloquine-treated mothers Africa do have babies with some very mild developmental delay in some specific motor skills.
Now I KNOW this is not directly relevant to the Australian veterans experience, but I think this suggests that some of the genetic and epigenetic effects on children that we have had some discussion about cannot (YET) be ruled out.
I'm not being alarmist, there are many studies that have shown no effect, but this is probably one of the largest, most consistently undertaken, and most importantly: is not linked to Roche.
What's sad to see too is the poor outcomes for these babies overall.
Wendy J.Seymour (Me)
Makes me wonder how many Australian female veterans have been affected in this way too with their pregnancy? Were some of them pregnant whilst being administered Mefloquine? Can the ADF or AMI or DVA explain that one to me please? The reason why I ask is our Mef n Taf veterans not only women but men are asking each other if they are experiencing certain symptoms in their special needs child/children and if these antimalarials have caused this. I've seen their posts on social media and I hang my head in shame with a feeling of helplessness.
Please refer to the document attached for further information. This is another matter that GPs and Specialists,Advocates ADF and DVA need to look at closely also.
Salinger : advocacy doses indexed to weight parturients for neuroprotection- ...
Magnesium sulphate for prevention of eclampsia: are intramuscular and intravenous
regimens equivalent? A population pharmacokinetic study
DOI: 10.1111/1471-0528.12222
www.bjog.org
WA 98195, USA. Email easter@u.washington.edu
Conclusions
"In summary, we have performed model-based PK analysis
on the concentration–time data from women with preeclampsia
treated with MgSO4. Several important clinical
observations can be made."....
First, the 4-g loading dose routinely
used in intravenous regimens provides lower initial
concentration than achieved with the intramuscular regimen.
Second, serum concentrations are low, and possibly subtherapeutic,
in a significant percentage of women in both
groups. Some of the variability is due to differences in
maternal weight, as a reflection of volume of distribution,
and to differences in serum creatinine concentration, as a
reflection of glomerular filtration rate.
The differences in extravascular volume due to oedema associated with preeclampsia
may also contribute to the variability in volume
of distribution. When local resources permit, individualisation
of dosing could be considered."
Bpa increases mammary cancer risk
This study examined the effects of bisphenol A (BPA) exposure on mammary cancer risk in mice. The researchers found that prenatal exposure to low and high doses of BPA led to earlier vaginal opening in female mouse offspring, indicating precocious puberty. While no differences in mammary gland development were observed, both BPA exposure groups had a statistically significant increase in susceptibility to mammary tumors induced by DMBA compared to controls. The study also found that BPA treatment promoted the growth of established MCF-7 human breast cancer tumors transplanted into mice, an effect that was reversed by tamoxifen treatment. The results suggest that BPA exposure may increase mammary cancer risk through at least two mechanisms: altering fetal mammary
Magnesium Sulfate for Cerebral Palsy Prevention
Magnesium Sulfate for Cerebral Palsy PreventionUniversity of Tennessee Memphis Obstetrics and Gyncology
This document summarizes the current literature on using magnesium sulfate for cerebral palsy prevention. It defines cerebral palsy and reviews studies showing magnesium sulfate may have neuroprotective effects by blocking calcium influx and glutamate receptors during hypoxic-ischemic injury. Several postnatal and antenatal studies are summarized, with meta-analyses finding magnesium sulfate reduces the risk of cerebral palsy, especially in very preterm infants under 30 weeks gestation. However, the evidence remains unclear and larger trials are still needed to establish efficacy and optimal dosing protocols.Ppt 25.9.16
The document summarizes 3 journal articles on the treatment of severe hypertension during pregnancy. The first article recommends intravenous labetalol and hydralazine as first-line therapies. It also recommends oral nifedipine and close monitoring of maternal and fetal status. The second article finds that low-dose aspirin initiated before 16 weeks of gestation reduces the risk of severe preeclampsia but not mild preeclampsia. The third article finds that oral nifedipine is as effective as intravenous antihypertensives for treating severe hypertension during pregnancy and postpartum, with similar safety profiles.
CƠ CHẾ PHÒNG NGỪA BẠO NÃO MgSO4
Magnesium sulfate is being studied for its potential neuroprotective effects in preventing cerebral palsy. Several studies have investigated administering magnesium sulfate either postnatally to newborns with hypoxic-ischemic encephalopathy or antenatally to mothers at risk of preterm birth. While some individual studies found magnesium sulfate improved short-term outcomes like reducing brain lesions or improving outcomes at hospital discharge, the larger trials found no clear statistically significant benefits. Overall the evidence remains unclear whether magnesium sulfate administration prevents long-term disabilities like cerebral palsy, though some studies found signals of potential benefit worth further investigation. Larger multicenter trials are still needed to provide more definitive evidence.
Maternal Sertraline Treatment And Serotonin Transport In Breast Feeding Mothe...
This study examined the effects of maternal sertraline treatment on serotonin transport in 14 breastfeeding mother-infant pairs. The researchers found that mothers receiving sertraline experienced substantial declines in platelet serotonin levels, indicating blockade of serotonin transporters. In contrast, the infants exposed to sertraline through breastfeeding showed little to no changes in platelet serotonin levels, suggesting their peripheral and central serotonin transport was not appreciably affected. The results indicate that mothers can safely take sertraline while breastfeeding without negatively impacting serotonin transport in their infants.
Update (2021) Oral Contraceptive Pill : Dr. Jyoti Agarwal Dr Sharda Jain
Update (2021) Oral Contraceptive Pill : Dr Sharda Jain
7 Billion 2011 & increasing a rate of 150 million per year
INDIA
Today – 1.3 billion 2050 – 1.628 expected
Comparison of prolonged low volume milk and routine volume milk on
This study compared outcomes for very low birth weight neonates who were fed using either a prolonged low volume milk strategy (20 mL/kg/day for 7 days before increasing) or a routine advancing volume strategy (increasing volumes by 20 mL/kg/day). The study found that the incidence of necrotizing enterocolitis was significantly lower in infants fed with the prolonged low volume strategy compared to those fed with advancing volumes. However, infants fed with advancing volumes reached full enteral feeding volumes sooner. Overall hospital stay times and weight gain at 30 days were similar between the two groups. The study suggests prolonged low volume feeding may help reduce NEC risk in very low birth weight neonates.
Therapeutic startegies for human papillomavirus infection and associated cancers
Human papillomavirus (HPV) infection is linked to development of cancer of cervix, vagina, vulva, penis, ano-genital and non-genital oro-pharyngeal sites. HPV being a sexually transmitted virus infects both genders equally but with higher chances of pathological outcome in women. In the absence of organized screening programs, women report HPV-infected lesions at relatively advanced stages where they are subjected to standard treatments that are not HPV-specific. HPV infection-driven lesions usually take 10–20 years for malignant progression and are preceded by well-characterized pre-cancer stages. Despite availability of window for pharmacological intervention, therapeutic that could eradicate HPV from infected lesions is currently lacking. A variety of experimental approaches have been made to address this lacuna and there has been significant progress in a number of lead molecules which are in different stages of clinical and pre-clinical development. Present review provides a brief overview of the magnitude of the problem and current status of research on promising lead molecules, formulations and therapeutic strategies that showed potential to translate to clinically-viable HPV therapeutics to counteract this reproductive health challenge
Cd009395
This review assessed the effectiveness of magnesium sulphate given to women at term as a neuroprotective agent for the fetus. The review included one randomized controlled trial involving 135 women with mild pre-eclampsia. The trial found no significant differences in infant outcomes like Apgar scores or gestational age between the magnesium sulphate and placebo groups. Mothers receiving magnesium sulphate reported more side effects like feeling warm and flushed. More research is needed to determine if magnesium sulphate provides neuroprotection for infants of mothers at term.
Broad spectrum antibiotics for preterm, prelabour rupture of fetal membranes-...
Broad spectrum antibiotics for preterm, prelabour rupture of fetal membranes-...ASTRID JOHANNA LONDOÑO ARANGO
This randomized controlled trial tested the effects of antibiotics (erythromycin and co-amoxiclav) on neonatal outcomes in women with preterm prelabor rupture of membranes (pPROM). 4826 women with pPROM were assigned to receive erythromycin, co-amoxiclav, both antibiotics, or placebo for 10 days or until delivery. Erythromycin was associated with reductions in the composite outcome of neonatal death, chronic lung disease or major brain abnormality compared to placebo, as well as prolongation of pregnancy and reductions in other neonatal complications. Co-amoxiclav provided no benefits and was associated with an increased risk of necrotizing enterocolitis. ErythPlan nacional-de-ss-y-sr-2017-2021
El plan promueve la inclusión, la igualdad y el respeto de los derechos humanos en materia de salud sexual y salud reproductiva en Ecuador. Establece lineamientos estratégicos y acciones para mejorar indicadores prioritarios como la mortalidad materna, el uso de anticonceptivos y la fecundidad entre adolescentes. Además, articula la gestión del sistema de salud para producir conocimiento sobre este tema e implementar estrategias que logren modificar dichos indicadores.
Mecanismodepartoobstetriciawilliams234aaa 181229023227
Este documento describe los mecanismos del parto, incluyendo la situación, presentación, actitud y variedad de posición del feto, los planos de Hodge, el desprendimiento y rotación externa de la cabeza fetal, y los signos de descenso de la placenta.
More Related Content
Similar to Nuevo documento de word 2007 (4)
1471 2393-13-91
This study aims to assess whether giving magnesium sulfate compared to placebo to women at risk of preterm birth between 30-34 weeks reduces the risk of death or cerebral palsy in children at two years. The study will randomly assign over 1600 women to receive either magnesium sulfate or placebo. The primary outcome measured will be death or cerebral palsy in children at two years. Previous studies have shown magnesium sulfate may reduce the risk of cerebral palsy in preterm infants, but the benefits at later gestational ages are uncertain, motivating this clinical trial.
Cd004661 abstract
This Cochrane review examines the effects of magnesium sulfate given to women at risk of preterm birth to protect the fetus's brain. The review found that magnesium sulfate significantly reduced the risk of cerebral palsy in preterm infants by 32% and reduced substantial gross motor dysfunction by 39%. No significant effects were found for pediatric mortality or other neurological impairments. Magnesium sulfate was found to have minor side effects for mothers but no significant effects on major maternal complications. The review concludes that magnesium sulfate has a established neuroprotective role for preterm fetuses.
Nej me0805018
This editorial discusses a recent randomized controlled trial that evaluated the use of bortezomib plus melphalan and prednisone compared to melphalan and prednisone alone for the initial treatment of multiple myeloma in patients who were not eligible for stem cell transplantation. The trial found that the combination of bortezomib provided superior outcomes, including higher response rates and longer duration of response. However, the editorial cautions that to effectively apply these results, comparisons need to be made to other available treatment options, long-term outcomes need to be evaluated, and toxic effects on quality of life considered. Overall progress is being made in multiple myeloma treatment, but further research is still needed.
01
1) Magnesium sulfate has been shown to provide neuroprotective effects for extremely premature infants by reducing cerebral injury and cell death.
2) While some studies found magnesium sulfate to be neuroprotective, others did not find sustainable effects, so more randomized studies were conducted.
3) A Cochrane review of 5 randomized trials found magnesium sulfate significantly reduced the risk of cerebral palsy in premature infants without increasing mortality risks for mother or infant.
Cd009395 standard
This review examines the effectiveness of magnesium sulfate given to women at term to protect the fetus from brain injury and neurodevelopmental disabilities like cerebral palsy. The review included one randomized controlled trial with 135 women with mild preeclampsia at term. The trial found no significant differences in infant outcomes like Apgar scores or gestational age between the magnesium sulfate and placebo groups. Maternal side effects were more common with magnesium sulfate, but severe side effects causing treatment cessation were similar between groups. Larger trials are still needed to determine if magnesium sulfate provides neuroprotection for infants when administered at term.
Bain et al-2014-bjog__an_international_journal_of_obstetrics_&_gynaecology
1) The study evaluated different loading infusion rates (60 minutes vs 20 minutes) of magnesium sulfate given to women before 30 weeks gestation for preterm fetal neuroprotection.
2) Overall, 71% of women experienced adverse effects during the first hour of infusion, with no significant difference between the 60-minute (60%) and 20-minute (81%) groups.
3) Women in the 60-minute group experienced significantly less warmth and flushing at 20 minutes into the infusion compared to the 20-minute group, but there were no other significant differences in adverse effects between the groups.
Magnesium sulfate
The document discusses evidence that magnesium sulfate administered to mothers at risk of preterm birth reduces the risk of cerebral palsy in infants. Several large randomized controlled trials and meta-analyses involving over 15,000 women found magnesium sulfate decreased the risk of cerebral palsy without increasing mortality. The number needed to treat to prevent one case of cerebral palsy is estimated at 63 women. The document also describes a modified magnesium sulfate neuroprotection protocol used at Riverside Hospital for imminent preterm deliveries between 23 and 33 weeks.
Magnesium sulfate
The document discusses evidence that magnesium sulfate administered to mothers at risk of preterm birth reduces the risk of cerebral palsy in infants. Several large randomized controlled trials and meta-analyses involving over 15,000 women found magnesium sulfate decreased the risk of cerebral palsy without increasing mortality. The number needed to treat to prevent one case of cerebral palsy is estimated at 63 women. The document also describes a modified magnesium sulfate neuroprotection protocol used at Riverside Hospital for imminent preterm deliveries between 23 and 33 weeks.
Health in infants born to mothers who received mefloquine or sulphadoxine pyr...
Attention ADF Female Veterans who were administered Mefloquine prior,during and after deployments overseas.
Dr Jane Quinn (Spokesperson for Mefloquine and Tafenoquine (Mef n Taf) Veterans Australia group)
BScu(U Westminister),PhD (Edin) quoted:
This study does show that mefloquine-treated mothers Africa do have babies with some very mild developmental delay in some specific motor skills.
Now I KNOW this is not directly relevant to the Australian veterans experience, but I think this suggests that some of the genetic and epigenetic effects on children that we have had some discussion about cannot (YET) be ruled out.
I'm not being alarmist, there are many studies that have shown no effect, but this is probably one of the largest, most consistently undertaken, and most importantly: is not linked to Roche.
What's sad to see too is the poor outcomes for these babies overall.
Wendy J.Seymour (Me)
Makes me wonder how many Australian female veterans have been affected in this way too with their pregnancy? Were some of them pregnant whilst being administered Mefloquine? Can the ADF or AMI or DVA explain that one to me please? The reason why I ask is our Mef n Taf veterans not only women but men are asking each other if they are experiencing certain symptoms in their special needs child/children and if these antimalarials have caused this. I've seen their posts on social media and I hang my head in shame with a feeling of helplessness.
Please refer to the document attached for further information. This is another matter that GPs and Specialists,Advocates ADF and DVA need to look at closely also.
Salinger : advocacy doses indexed to weight parturients for neuroprotection- ...
Magnesium sulphate for prevention of eclampsia: are intramuscular and intravenous
regimens equivalent? A population pharmacokinetic study
DOI: 10.1111/1471-0528.12222
www.bjog.org
WA 98195, USA. Email easter@u.washington.edu
Conclusions
"In summary, we have performed model-based PK analysis
on the concentration–time data from women with preeclampsia
treated with MgSO4. Several important clinical
observations can be made."....
First, the 4-g loading dose routinely
used in intravenous regimens provides lower initial
concentration than achieved with the intramuscular regimen.
Second, serum concentrations are low, and possibly subtherapeutic,
in a significant percentage of women in both
groups. Some of the variability is due to differences in
maternal weight, as a reflection of volume of distribution,
and to differences in serum creatinine concentration, as a
reflection of glomerular filtration rate.
The differences in extravascular volume due to oedema associated with preeclampsia
may also contribute to the variability in volume
of distribution. When local resources permit, individualisation
of dosing could be considered."
Bpa increases mammary cancer risk
This study examined the effects of bisphenol A (BPA) exposure on mammary cancer risk in mice. The researchers found that prenatal exposure to low and high doses of BPA led to earlier vaginal opening in female mouse offspring, indicating precocious puberty. While no differences in mammary gland development were observed, both BPA exposure groups had a statistically significant increase in susceptibility to mammary tumors induced by DMBA compared to controls. The study also found that BPA treatment promoted the growth of established MCF-7 human breast cancer tumors transplanted into mice, an effect that was reversed by tamoxifen treatment. The results suggest that BPA exposure may increase mammary cancer risk through at least two mechanisms: altering fetal mammary
Magnesium Sulfate for Cerebral Palsy Prevention
Magnesium Sulfate for Cerebral Palsy PreventionUniversity of Tennessee Memphis Obstetrics and Gyncology
This document summarizes the current literature on using magnesium sulfate for cerebral palsy prevention. It defines cerebral palsy and reviews studies showing magnesium sulfate may have neuroprotective effects by blocking calcium influx and glutamate receptors during hypoxic-ischemic injury. Several postnatal and antenatal studies are summarized, with meta-analyses finding magnesium sulfate reduces the risk of cerebral palsy, especially in very preterm infants under 30 weeks gestation. However, the evidence remains unclear and larger trials are still needed to establish efficacy and optimal dosing protocols.Ppt 25.9.16
The document summarizes 3 journal articles on the treatment of severe hypertension during pregnancy. The first article recommends intravenous labetalol and hydralazine as first-line therapies. It also recommends oral nifedipine and close monitoring of maternal and fetal status. The second article finds that low-dose aspirin initiated before 16 weeks of gestation reduces the risk of severe preeclampsia but not mild preeclampsia. The third article finds that oral nifedipine is as effective as intravenous antihypertensives for treating severe hypertension during pregnancy and postpartum, with similar safety profiles.
CƠ CHẾ PHÒNG NGỪA BẠO NÃO MgSO4
Magnesium sulfate is being studied for its potential neuroprotective effects in preventing cerebral palsy. Several studies have investigated administering magnesium sulfate either postnatally to newborns with hypoxic-ischemic encephalopathy or antenatally to mothers at risk of preterm birth. While some individual studies found magnesium sulfate improved short-term outcomes like reducing brain lesions or improving outcomes at hospital discharge, the larger trials found no clear statistically significant benefits. Overall the evidence remains unclear whether magnesium sulfate administration prevents long-term disabilities like cerebral palsy, though some studies found signals of potential benefit worth further investigation. Larger multicenter trials are still needed to provide more definitive evidence.
Maternal Sertraline Treatment And Serotonin Transport In Breast Feeding Mothe...
This study examined the effects of maternal sertraline treatment on serotonin transport in 14 breastfeeding mother-infant pairs. The researchers found that mothers receiving sertraline experienced substantial declines in platelet serotonin levels, indicating blockade of serotonin transporters. In contrast, the infants exposed to sertraline through breastfeeding showed little to no changes in platelet serotonin levels, suggesting their peripheral and central serotonin transport was not appreciably affected. The results indicate that mothers can safely take sertraline while breastfeeding without negatively impacting serotonin transport in their infants.
Update (2021) Oral Contraceptive Pill : Dr. Jyoti Agarwal Dr Sharda Jain
Update (2021) Oral Contraceptive Pill : Dr Sharda Jain
7 Billion 2011 & increasing a rate of 150 million per year
INDIA
Today – 1.3 billion 2050 – 1.628 expected
Comparison of prolonged low volume milk and routine volume milk on
This study compared outcomes for very low birth weight neonates who were fed using either a prolonged low volume milk strategy (20 mL/kg/day for 7 days before increasing) or a routine advancing volume strategy (increasing volumes by 20 mL/kg/day). The study found that the incidence of necrotizing enterocolitis was significantly lower in infants fed with the prolonged low volume strategy compared to those fed with advancing volumes. However, infants fed with advancing volumes reached full enteral feeding volumes sooner. Overall hospital stay times and weight gain at 30 days were similar between the two groups. The study suggests prolonged low volume feeding may help reduce NEC risk in very low birth weight neonates.
Therapeutic startegies for human papillomavirus infection and associated cancers
Human papillomavirus (HPV) infection is linked to development of cancer of cervix, vagina, vulva, penis, ano-genital and non-genital oro-pharyngeal sites. HPV being a sexually transmitted virus infects both genders equally but with higher chances of pathological outcome in women. In the absence of organized screening programs, women report HPV-infected lesions at relatively advanced stages where they are subjected to standard treatments that are not HPV-specific. HPV infection-driven lesions usually take 10–20 years for malignant progression and are preceded by well-characterized pre-cancer stages. Despite availability of window for pharmacological intervention, therapeutic that could eradicate HPV from infected lesions is currently lacking. A variety of experimental approaches have been made to address this lacuna and there has been significant progress in a number of lead molecules which are in different stages of clinical and pre-clinical development. Present review provides a brief overview of the magnitude of the problem and current status of research on promising lead molecules, formulations and therapeutic strategies that showed potential to translate to clinically-viable HPV therapeutics to counteract this reproductive health challenge
Cd009395
This review assessed the effectiveness of magnesium sulphate given to women at term as a neuroprotective agent for the fetus. The review included one randomized controlled trial involving 135 women with mild pre-eclampsia. The trial found no significant differences in infant outcomes like Apgar scores or gestational age between the magnesium sulphate and placebo groups. Mothers receiving magnesium sulphate reported more side effects like feeling warm and flushed. More research is needed to determine if magnesium sulphate provides neuroprotection for infants of mothers at term.
Broad spectrum antibiotics for preterm, prelabour rupture of fetal membranes-...
Broad spectrum antibiotics for preterm, prelabour rupture of fetal membranes-...ASTRID JOHANNA LONDOÑO ARANGO
This randomized controlled trial tested the effects of antibiotics (erythromycin and co-amoxiclav) on neonatal outcomes in women with preterm prelabor rupture of membranes (pPROM). 4826 women with pPROM were assigned to receive erythromycin, co-amoxiclav, both antibiotics, or placebo for 10 days or until delivery. Erythromycin was associated with reductions in the composite outcome of neonatal death, chronic lung disease or major brain abnormality compared to placebo, as well as prolongation of pregnancy and reductions in other neonatal complications. Co-amoxiclav provided no benefits and was associated with an increased risk of necrotizing enterocolitis. ErythSimilar to Nuevo documento de word 2007 (4) (20)
Bain et al-2014-bjog__an_international_journal_of_obstetrics_&_gynaecology
Bain et al-2014-bjog__an_international_journal_of_obstetrics_&_gynaecology
Health in infants born to mothers who received mefloquine or sulphadoxine pyr...
Health in infants born to mothers who received mefloquine or sulphadoxine pyr...
Salinger : advocacy doses indexed to weight parturients for neuroprotection- ...
Salinger : advocacy doses indexed to weight parturients for neuroprotection- ...
Maternal Sertraline Treatment And Serotonin Transport In Breast Feeding Mothe...
Maternal Sertraline Treatment And Serotonin Transport In Breast Feeding Mothe...
Update (2021) Oral Contraceptive Pill : Dr. Jyoti Agarwal Dr Sharda Jain
Update (2021) Oral Contraceptive Pill : Dr. Jyoti Agarwal Dr Sharda Jain
Comparison of prolonged low volume milk and routine volume milk on
Comparison of prolonged low volume milk and routine volume milk on
Therapeutic startegies for human papillomavirus infection and associated cancers
Therapeutic startegies for human papillomavirus infection and associated cancers
Broad spectrum antibiotics for preterm, prelabour rupture of fetal membranes-...
Broad spectrum antibiotics for preterm, prelabour rupture of fetal membranes-...
More from Jaime Zapata Salazar
Plan nacional-de-ss-y-sr-2017-2021
El plan promueve la inclusión, la igualdad y el respeto de los derechos humanos en materia de salud sexual y salud reproductiva en Ecuador. Establece lineamientos estratégicos y acciones para mejorar indicadores prioritarios como la mortalidad materna, el uso de anticonceptivos y la fecundidad entre adolescentes. Además, articula la gestión del sistema de salud para producir conocimiento sobre este tema e implementar estrategias que logren modificar dichos indicadores.
Mecanismodepartoobstetriciawilliams234aaa 181229023227
Este documento describe los mecanismos del parto, incluyendo la situación, presentación, actitud y variedad de posición del feto, los planos de Hodge, el desprendimiento y rotación externa de la cabeza fetal, y los signos de descenso de la placenta.
Gpc hta192019
Este documento presenta una guía de práctica clínica sobre hipertensión arterial desarrollada por el Ministerio de Salud Pública del Ecuador. La guía provee recomendaciones sobre prevención, diagnóstico, tratamiento y seguimiento de pacientes hipertensos. El objetivo es asistir a profesionales de la salud en la toma de decisiones sobre esta condición. La guía fue adaptada de lineamientos internacionales mediante un proceso que incluyó revisión de evidencia y consenso de expertos.
Msp consentimiento informado--am-5316
Este documento presenta el Modelo de gestión de aplicación del consentimiento informado en la práctica asistencial, de acuerdo con el Acuerdo Ministerial 5316. Explica la importancia del consentimiento informado, los modelos de relación médico-paciente, y extractos de normas relacionadas con el consentimiento informado en Ecuador. Además, resume los objetivos, condiciones y responsables del proceso de consentimiento informado, y provee un modelo de formulario de consentimiento informado escrito.
Gp tuberculosis 1 / https://www.salud.gob.ec/guias-de-practica-clinica/
Guía de práctica clínica Tuberculosis
Prevención, diagnóstico , tratamiento y control de Tuberculosis
https://www.salud.gob.ec/guias-de-practica-clinica/
Guia prevencion diagnostico_tratamiento_enfermedad_renal_cronica_2018
Esta guía de práctica clínica del Ministerio de Salud Pública del Ecuador tiene como objetivo proporcionar recomendaciones para la prevención, diagnóstico y tratamiento de la enfermedad renal crónica. Fue desarrollada por un equipo multidisciplinario de expertos y revisada por pares. La guía resume las principales evidencias científicas disponibles sobre la enfermedad renal crónica y ofrece orientación para profesionales de la salud sobre el manejo clínico de esta patología.
Diabetes 2019
El resumen describe los principales cambios en las recomendaciones de 2019 de la Guía de la Asociación Americana de Diabetes sobre el tratamiento y atención de la diabetes. Entre los cambios se incluyen: preferir un agonista del receptor del péptido similar al glucagón en lugar de insulina para pacientes con diabetes tipo 2 que requieren medicamentos inyectables; limitar el beneficio adicional del autocontrol rutinario de glucosa para pacientes con diabetes tipo 2 que no usan insulina; y enfatizar la evaluación del riesgo cardiovascular, la ingesta de agua y
Gpc vih acuerdo_ministerial05-07-2019
Este documento presenta una guía de práctica clínica sobre la prevención, diagnóstico y tratamiento de la infección por VIH en embarazadas, niños, adolescentes y adultos en Ecuador. La guía fue desarrollada por el Ministerio de Salud Pública a través de un proceso de adaptación de guías internacionales y consenso nacional, con el objetivo de orientar a los profesionales de la salud en la atención clínica de estas poblaciones. La guía incluye recomendaciones actualizadas sobre prevención
Gpc hta192019
Este documento presenta una guía de práctica clínica sobre hipertensión arterial desarrollada por el Ministerio de Salud Pública de Ecuador. La guía define hipertensión arterial, explica su fisiopatología e historia natural, y establece recomendaciones para la prevención, detección, diagnóstico y tratamiento basadas en evidencia científica. La guía busca asistir a profesionales de la salud y pacientes en la toma de decisiones sobre el manejo clínico de la hipertensión.
Gpc ehirn2019
Esta guía de práctica clínica trata sobre la encefalopatía hipóxica isquémica en recién nacidos y contiene información sobre: 1) la clasificación, diagnóstico diferencial y fisiopatología de esta condición; 2) los aspectos metodológicos considerados en la guía; y 3) las evidencias y recomendaciones para el manejo clínico de los pacientes. La guía fue desarrollada por el Ministerio de Salud Pública del Ecuador y varios hospitales del país con el objetivo de prove
Scoremamá 2017 170316131010-171107014356 (1)
Este documento presenta el protocolo Score MAMÁ y claves obstétricas desarrollado por el Ministerio de Salud Pública de Ecuador. Incluye la herramienta Score MAMÁ para evaluar signos vitales y nivel de conciencia en mujeres embarazadas o puérperas, así como claves de color (roja, azul y amarilla) para la clasificación y manejo de emergencias obstétricas. El objetivo es estandarizar la atención prehospitalaria y de primer nivel para la detección temprana y referencia oportuna de complic
Estrategia reduccion-muerte-materna[1]
Este documento presenta información sobre la mortalidad materna en Ecuador. Las metas nacionales buscan reducir la razón de mortalidad materna a 40 por cada 100,000 nacidos vivos para el 2017. Se describen las principales causas de muerte materna y se enfatiza la importancia de la planificación familiar y la atención obstétrica de calidad para prevenir estas muertes. Finalmente, se propone la estrategia "Alarma Materna" para mejorar la detección oportuna de complicaciones y la derivación a un nivel de atención adecuado
Protocolo muerte encefalica_version-digital
Este documento presenta el protocolo para el diagnóstico y certificación de la muerte encefálica en Ecuador. Describe los criterios neurológicos para realizar el diagnóstico, incluyendo un examen clínico sistemático y riguroso que confirme la ausencia de reflejos del tronco cerebral y respiración espontánea. También establece la importancia de contar con médicos expertos capacitados para realizar este diagnóstico de gran responsabilidad médico-legal, y la necesidad de disponer de instrumentos normat
Manual ss-discapacidades-finalweb-1
Este manual presenta lineamientos para la atención integral de la salud sexual y reproductiva de las personas con discapacidad en Ecuador. Reconoce que históricamente este grupo poblacional ha enfrentado barreras para acceder a estos servicios debido a imaginarios y prácticas que los infantilizan o los consideran asexuados. El documento identifica barreras sociales, culturales, de comunicación, arquitectónicas y de equipamiento, y propone mecanismos para superarlas. También presenta consideraciones generales y lineamientos específicos
Manual para-la-gestion-de-la-asistencia-humanitaria-internacional
Este manual presenta los principios y procedimientos para la gestión de la asistencia humanitaria internacional en situaciones de emergencia y desastre en Ecuador. Detalla las entidades involucradas como la Secretaría de Gestión de Riesgos y el Ministerio de Relaciones Exteriores, y explica los escenarios en los que Ecuador puede participar como país receptor, asistente o facilitador de cooperación internacional. Además, incluye flujogramas y protocolos para coordinar de manera efectiva la ayuda entre los diferentes actores durante una emergencia.
Investigación en salud 2004
Este documento provee una guía integral para la investigación en salud. Explica los principios básicos y métodos de investigación cualitativa y cuantitativa, y destaca la importancia de los principios éticos en todo el proceso de investigación. Además, brinda referencias actualizadas para aquellos interesados en aprender más sobre los temas cubiertos.
Guia de transfusión de sangre y sus componentes
Esta guía de práctica clínica proporciona evidencias y recomendaciones sobre la transfusión de sangre y sus componentes como concentrados de glóbulos rojos, concentrados de plaquetas y plasma fresco congelado. La guía fue desarrollada por un equipo multidisciplinario de expertos en Ecuador con el objetivo de asistir a médicos en la toma de decisiones sobre la transfusión de sangre. La guía incluye definiciones de los componentes de la sangre, recomendaciones para diferentes indicaciones clínicas como cirugía
Guia de ciudadan trastornos hipertensivos del embarazo
La Unión Europea ha propuesto un nuevo paquete de sanciones contra Rusia que incluye un embargo al petróleo. El embargo prohibiría la importación de petróleo ruso a la UE y también impediría el acceso de buques rusos a puertos europeos. Sin embargo, Hungría se opone firmemente al embargo al petróleo, argumentando que su economía depende en gran medida de las importaciones de energía rusa.
Gpc anomalias-insercion-placentaria-17-01-2017-1
Esta guía presenta recomendaciones sobre el diagnóstico, manejo y tratamiento de las anomalías de inserción placentaria como la placenta previa, el acretismo placentario y la vasa previa. Proporciona una clasificación de estas condiciones y discute factores de riesgo, manifestaciones clínicas, diagnóstico, manejo prenatal, tratamiento específico y criterios de referencia. El objetivo es asistir a los profesionales de la salud en la toma de decisiones sobre el manejo de estas patologías obstétricas.
More from Jaime Zapata Salazar (20)
Mecanismodepartoobstetriciawilliams234aaa 181229023227
Mecanismodepartoobstetriciawilliams234aaa 181229023227
Gp tuberculosis 1 / https://www.salud.gob.ec/guias-de-practica-clinica/
Gp tuberculosis 1 / https://www.salud.gob.ec/guias-de-practica-clinica/
Guia prevencion diagnostico_tratamiento_enfermedad_renal_cronica_2018
Guia prevencion diagnostico_tratamiento_enfermedad_renal_cronica_2018
Manual para-la-gestion-de-la-asistencia-humanitaria-internacional
Manual para-la-gestion-de-la-asistencia-humanitaria-internacional
Guia de ciudadan trastornos hipertensivos del embarazo
Guia de ciudadan trastornos hipertensivos del embarazo
Nuevo documento de word 2007 (4)
- 1. BMC Pregnancy Childbirth. 2013 Apr 9;13:91. doi: 10.1186/1471-2393-13-91. Magnesium sulphate at 30 to 34 weeks' gestationalage: neuroprotectiontrial (MAGENTA)--studyprotocol. Crowther CA1 , Middleton PF, Wilkinson D, Ashwood P, Haslam R; MAGENTA Study Group. Author information 1 Australian Research Centre for Health of Women and Babies (ARCH), The Robinson Institute, The University of Adelaide, Adelaide, Australia. caroline.crowther@adelaide.edu.au Abstract BACKGROUND: Magnesium sulphate is currently recommended for neuroprotection of preterm infants for women at risk of preterm birth at less than 30 weeks' gestation, based on high quality evidence of benefit. However there remains uncertainty as to whether these benefits apply at higher gestational ages.The aim of this randomised controlled trial is to assess whether giving magnesium sulphate compared with placebo to women immediately prior to preterm birth between 30 and 34 weeks' gestation reduces the risk of death or cerebral palsy in their children at two years' corrected age. METHODS/DESIGN: DESIGN: Randomised, multicentre, placebo controlled trial. INCLUSION CRITERIA: Women, giving informed consent, at risk of preterm birth between 30 to 34 weeks' gestation, where birth is planned or definitely expected within 24 hours, with a singleton or twin pregnancy and no contraindications to the use of magnesium sulphate.Trial entry & randomisation: Eligible women will be randomly allocated to receive either magnesium sulphate or placebo.Treatment groups: Women in the magnesium sulphate group will be administered 50 ml of a 100 ml infusion bag containing 8 g magnesium sulphate heptahydrate [16 mmol magnesium ions]. Women in the placebo group will be administered 50 ml of a 100 ml infusion bag containing isotonic sodium chloride solution (0.9%). Both treatments will be administered through a dedicated IV infusion line over 30 minutes.Primary study outcome: Death or cerebral palsy measured in children at two years' corrected age. SAMPLE SIZE: 1676 children are required to detect a decrease in the combined outcome of death or cerebral palsy, from 9.6% with placebo to 5.4% with magnesium sulphate (two-sided alpha 0.05, 80% power, 5% loss to follow up, design effect 1.2). DISCUSSION:
- 2. Given the magnitude of the protective effect in the systematic review, the ongoing uncertainty about benefits at later gestational ages, the serious health and cost consequences of cerebral palsy for the child, family and society, a trial of magnesium sulphate for women at risk of preterm birth between 30 to 34 weeks' gestation is both important and relevant for clinical practice globally. TRIAL REGISTRATION: Australian New Zealand Clinical Trials Registry - ACTRN12611000491965. PMID: 23570677 [PubMed - indexed for MEDLINE] PMCID: PMC3636106 Free PMC Article